Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 4, 2014, Pages 99-106

  Latorre, Elisa ^a,b   Castiglioni, Ilaria ^a   Gatto, Pamela ^a   Carelli, Stephana ^b   Quattrone, Alessandro ^a   Provenzani, Alessandro ^a  

^a UNIVERSITY OF TRENTO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE C-DELTA; RNA, SMALL INTERFERING;

EID: 84896445788     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211839     Document Type: Article

References (30)

1. Anantharam V, Kitazawa M, Wagner J, Kaul S, and Kanthasamy AG (2002) Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J Neurosci 22:1738-1751.
2. Bertini I, Gelis I, Katsaros N, Luchinat C, and Provenzani A (2003) Tuning the affinity for lanthanides of calcium binding proteins. Biochemistry 42:8011-8021.
3. Broxterman HJ, Gotink KJ, and Verheul HMW (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12:114-126.
4. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, and Brody JR (2009) The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 69:4567-4572.
5. D'Agostino VG, Adami V, and Provenzani A (2013) A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. PLoS ONE 8:e72426.
6. Dassi E, Zuccotti P, Leo S, Provenzani A, Assfalg M, D'Onofrio M, Riva P, and Quattrone A (2013) Hyper conserved elements in vertebrate mRNA 39-UTRs reveal a translational network of RNA-binding proteins controlled by HuR. Nucleic Acids Res 41:3201-3216.
7. Doller A, Gauer S, Sobkowiak E, Geiger H, Pfeilschifter J, and Eberhardt W (2009) Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor humanantigen R. Am J Pathol 174:1252-1263.
8. Doller A, Schlepckow K, Schwalbe H, Pfeilschifter J, and Eberhardt W (2010) Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. Mol Cell Biol 30: 1397-1410.
9. Doller A, Winkler C, Azrilian I, Schulz S, Hartmann S, Pfeilschifter J, and Eberhardt W (2011) High-constitutive HuR phosphorylation at Ser 318 by PKCdelta propagates tumor relevant functions in colon carcinoma cells. Carcinogenesis 32: 676-685.
10. Eberhardt W, Doller A, and Pfeilschifter J (2012) Regulation of the mRNA-binding protein HuR by posttranslational modification: spotlight on phosphorylation. Curr Protein Pept Sci 13:380-390.
11. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, and Ivanova EV, et al. (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2:934-947.
12. Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, Wheeler C, and Nabors LB (2011) The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res 9:648-659.
13. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, and Hickson ID (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592-6595.
14. Gonzalez-Guerrico AM and Kazanietz MG (2005) Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J Biol Chem 280:38982-38991.
15. Gros P, Ben Neriah YB, Croop JM, and Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731.
16. Gschwendt M, Müller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, and Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93-98.
17. Hinman MN and Lou H (2008) Diverse molecular functions of Hu proteins. Cell Mol Life Sci 65:3168-3181.
18. Lasfer M, Davenne L, Vadrot N, Alexia C, Sadji-Ouatas Z, Bringuier A-F, Feldmann G, Pessayre D, and Reyl-Desmars F (2006) Protein kinase PKC delta and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor. FEBS Lett 580:2547-2552.
19. Latorre E, Tebaldi T, Viero G, Spartà AM, Quattrone A, and Provenzani A (2012) Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer 11:13.
20. Leitges M, Mayr M, Braun U, Mayr U, Li C, Pfister G, Ghaffari-Tabrizi N, Baier G, Hu Y, and Xu Q (2001) Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest 108:1505-1512.
21. Mellor H and Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281-292.
22. Mukherjee N, Lager PJ, Friedersdorf MB, Thompson MA, and Keene JD (2009) Coordinated posttranscriptional mRNA population dynamics during T-cell activation. Mol Syst Biol 5:288.
23. Panaretakis T, Laane E, Pokrovskaja K, Björklund A-C, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, and Grandér D (2005) Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 16:3821-3831.
24. Pascale A and Govoni S (2012) The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNAbinding proteins. Cell Mol Life Sci 69:501-517.
25. Schulz S, Doller A, Pendini NR, Wilce JA, Pfeilschifter J, and Eberhardt W (2013) Domain-specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) isotype-triggered activities of the RNA binding protein HuR. Cell Signal 25:2485-2495.
26. Soltoff SP (2007) Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 28:453-458.
27. Srikantan S, Abdelmohsen K, Lee EK, Tominaga K, Subaran SS, Kuwano Y, Kulshrestha R, Panchakshari R, Kim HH, and Yang X, et al. (2011) Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol 31:3790-3801.
28. Srikantan S and Gorospe M (2012) HuR function in disease. Front Biosci (Landmark Ed) 17:189-205.
29. Vázquez-Chantada M, Fernández-Ramos D, Embade N, Martínez-Lopez N, Varela-Rey M, Woodhoo A, Luka Z, Wagner C, Anglim PP, and Finnell RH, et al. (2010) HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology 138:1943-1953.
30. Wang J, Li D, Wang B, and Wu Y (2013) Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 141:213-224.